Accelerate Diagnostics Stock News

Can these penny stocks make gains this month? The post Best Penny Stocks to Buy Now?

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Laura Pierson – Investor Relations Jack Phillips – Chief Executive Officer

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) delivered earnings and revenue surprises of -30% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.79, reflecting an intraday loss of -5.29% or -$0.1. The 52-week high for the AXDX share is $9.79, that puts it down … Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week? Read More »

Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13, compared to year-ago

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 23.33% and 3.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Accelerate Diagnostics press release (AXDX): Q4 GAAP EPS of -$0.34.Revenue of $3.3M (+6.5% Y/Y).

Accelerate Diagnostics' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 23.33% and 3.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas